Sign in to fuzzto save your conversations, follow your research and come back anytime.
Transpek Industry
TRANSPEK
NSE
BSE
NSEBSESectorChemicals
1,390.00
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Transpek Industry stabilizes earnings after a tough FY26, driven by a sharp pivot to domestic markets and specialty chemicals despite rising input costs.
Finance costs drop from ₹2.5 Cr in Q1 FY26 to ₹1.5 Cr in Q1 FY27, lowering interest burden.
Material consumption costs jump from ₹62.2 Cr in Q4 FY26 to ₹87.2 Cr in Q1 FY27, squeezing production margins.
Domestic revenue share grows from 17.3% in Q1 FY26 to 32.7% in Q1 FY27, strengthening local market presence.
International revenue share drops from 83.9% in Q2 FY26 to 22.34% in Q1 FY27, reflecting a major geographic shift.
Specialty chemicals mix expands from 6.8% in Q3 FY26 to 22.5% in Q1 FY27, diversifying the product portfolio.
Polymers revenue mix contracts from 68.5% in Q3 FY26 to 48.7% in Q1 FY27, reducing core segment reliance.
European revenue share rebounds from 9.3% in Q2 FY26 to 16.9% in Q1 FY27, restoring regional demand.
Inventory changes reverse to -₹14.6 Cr in Q1 FY27 from ₹10.0 Cr in Q4 FY26, signaling aggressive destocking.
Employee expenses stabilize at ₹18.4 Cr in Q1 FY27 after fluctuating between ₹18.1 Cr and ₹19.2 Cr in FY26, keeping payroll predictable.
EBITDA margin recovers to 15.6% in Q1 FY27 from 14.4% in Q4 FY26, but remains below the 21.5% peak in Q1 FY26.
